ストックスクリーナーアプリを入手
0.00
100.00%
-53.01
アフターアワーズ：
53.02
53.02
+
前日終値:
$53.01
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$2.76B
収益：
$285.01M
当期純損益:
$95.63M
株価収益率:
0.00
EPS:
1.762
ネットキャッシュフロー:
$105.42M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
名前
Soleno Therapeutics Inc
セクター
電話
650-213-8444
住所
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
0.00 | 2.76B | 285.01M | 95.63M | 105.42M | 1.762 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-18 | 開始されました | Wolfe Research | Outperform |
| 2025-10-07 | 開始されました | Goldman | Buy |
| 2025-08-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-23 | 開始されました | TD Cowen | Buy |
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2024-12-02 | 繰り返されました | Robert W. Baird | Outperform |
| 2024-12-02 | 繰り返されました | Stifel | Buy |
| 2024-09-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-10 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-05 | 開始されました | Piper Sandler | Overweight |
| 2024-01-23 | 開始されました | Stifel | Buy |
| 2023-11-21 | 再開されました | Guggenheim | Buy |
| 2020-09-29 | 開始されました | Guggenheim | Buy |
| 2020-01-10 | 開始されました | Craig Hallum | Buy |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2018-02-13 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Soleno Therapeutics Inc (SLNO) 最新ニュース
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring the Healthcare Biotech Leader’s Steady Trajectory - DirectorsTalk Interviews
SLNO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Soleno Therapeutics (SLNO) Holds Steady at $53.01: Consolidation Within Key BoundariesFactor Crowding - newsline.com
Neurocrine to acquire Soleno Therapeutics for $2.9 billion By Investing.com - Investing.com Australia
NBIX Stock Draws Bullish Targets After Soleno Deal - StocksToTrade
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
NBIX: Multi-product growth, major acquisition, and robust pipeline drive strong financial and patient impact - TradingView
Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating By Investing.com - Investing.com Canada
Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating - Investing.com
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating Zero Upside but Strong Cash Flow - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Reach Out - ACCESS Newswire
SLNO Technical Analysis & Stock Price Forecast - Intellectia AI
2026-05-31 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Investors to Reach Out | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Reach Out - ACCESS Newswire
[15-12G] SOLENO THERAPEUTICS INC SEC Filing - Stock Titan
[EFFECT] SOLENO THERAPEUTICS INC SEC Filing - Stock Titan
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Stockholders to Connect - ACCESS Newswire
Soleno Therapeutics (SLNO) Investor Outlook: Navigating the Hold Ratings with Promising EPS and Cash Flow - DirectorsTalk Interviews
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Soleno Therapeutics (NASDAQ: SLNO) deregisters 3,000,000-share resale after merger - Stock Titan
SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
News On Soleno Therapeutics Inc. (SLNO) Now Under NBIX - Moomoo
Soleno Therapeutics, Inc.(NasdaqGM: ) dropped from Russell 3000 Growth Index - marketscreener.com
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - Sahm
Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics - Moomoo
Merger cashes out Soleno (NASDAQ: SLNO) officer equity at $53 - Stock Titan
Soleno Therapeutics (SLNO) director’s shares and options cancelled for $53 cash in Neurocrine merger - Stock Titan
Soleno Therapeutics (SLNO) director equity canceled in $53-per-share merger - Stock Titan
Soleno (SLNO) director’s shares cashed out at $53 per-share merger price - Stock Titan
Soleno Therapeutics (SLNO) CBO equity canceled, cashed out at $53 per share - Stock Titan
Soleno Therapeutics (SLNO) CCO equity cancelled, converted to $53 cash in merger - Stock Titan
Soleno Therapeutics (SLNO) CDO equity cancelled for $53 cash in merger - Stock Titan
Soleno (SLNO) SVP exits equity as merger pays $53 per share - Stock Titan
Soleno Therapeutics (SLNO) insider equity cashed out at $53 in Neocrine merger - Stock Titan
Soleno (SLNO) director’s 10,046 RSUs canceled for $53 cash in merger - Stock Titan
Soleno Therapeutics (SLNO) CFO has RSUs and stock options cashed out in Neocrine merger - Stock Titan
Soleno Therapeutics (SLNO) director exits as $53-per-share cash merger closes - Stock Titan
Soleno Therapeutics (SLNO) CEO fully cashed out as $53-per-share merger closes - Stock Titan
Neurocrine Biosciences completes $2.9 billion Soleno acquisition - Investing.com UK
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others. - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics, Adds VYKAT XR for Prader-Willi Syndrome to Rare Disease Portfolio - Minichart
Soleno Therapeutics Announces Acquisition by Neurocrine Biosciences and Corporate Changes – SEC Form 8-K Filing - Minichart
Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq - Investing.com Nigeria
Soleno Therapeutics Inc (SLNO) 財務データ
収益
当期純利益
現金流量
EPS
1.04%
0.76%
大文字化:
|
ボリューム (24 時間):